Skip to main content
PsyBio Therapeutics Corp. logo

PsyBio Therapeutics Corp. — Investor Relations & Filings

Ticker · PSYBF ISIN · CA74464R1000 LEI · 549300KO32JSWBZIZP18 TSXV Manufacturing
Open in API
Filings indexed 119 across all filing types
Latest filing 2021-10-21 Capital/Financing Update
Country CA Canada
Listing TSXV PSYBF

About PsyBio Therapeutics Corp.

www.psybiolife.com

PsyBio Therapeutics Corp. is an intellectual property-driven biotechnology company focused on the discovery, design, and development of psycho-targeted therapeutics for mental and neurological conditions, including CNS disorders. The company develops a portfolio of novel psychoactive compounds and their analogues. A key differentiator is its proprietary platform utilizing genetically modified bacteria for the scalable, biosynthetic manufacturing of psychoactive molecules, such as tryptamines. PsyBio is actively engaged in preclinical studies and developing its own compounds, aiming to improve treatments for various psychologic and neurologic conditions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that PsyBio Therapeutics Corp.'s subordinate voting shares are now eligible for electronic clearing and settlement through the Depository Trust Company (DTC). It discusses the implications of this eligibility for liquidity and trading but does not contain any financial statements, detailed financial results, or regulatory filings. There is no indication of an annual or quarterly report, audit report, management changes, or other specific filings. The content is an announcement about a capital market operational update related to share trading and settlement. This fits best under Capital/Financing Update (CAP) as it relates to the company's capital market activities and share trading facilitation. The document length and content confirm it is not a brief report publication announcement or a regulatory filing. Confidence is high due to clear focus on DTC eligibility and trading liquidity.
2021-10-21 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that PsyBio Therapeutics has successfully demonstrated commercial scale manufacturing feasibility for one of its therapeutic candidates. It discusses the company's progress, technology scale-up, and future plans for manufacturing and clinical development. There are no financial statements, regulatory filings, or detailed financial data presented. The document is a corporate announcement about operational progress rather than a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate news announcement about manufacturing capability and development progress, which aligns best with a Regulatory Filings (RNS) classification as a general regulatory announcement or corporate update that does not fit other specific categories.
2021-10-07 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the company's participation in upcoming investor conferences in September 2021. It includes details about the events, dates, and contact information for scheduling meetings. There is no financial data, no report attached or referenced as being published, no voting results, no management changes, no legal proceedings, no capital updates, and no earnings or interim report data. The document is essentially a corporate announcement about investor relations activities and conference participation. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and corporate news that do not fit other specific categories.
2021-09-20 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that PsyBio Therapeutics has been included in the AdvisorShares Psychedelics Exchange Traded Fund (ETF). It contains no financial statements, no detailed financial performance data, no regulatory filings, no management or board changes, no voting results, no legal proceedings, and no mention of any report publication. The content is primarily an announcement of a corporate event related to the company's inclusion in an ETF, which is a capital market update. This fits best under Capital/Financing Update (CAP) as it relates to the company's market exposure and investor relations. The document length is 7612 characters, which is sufficient for a detailed announcement but does not contain financial reports or transcripts. Therefore, the classification is CAP with high confidence.
2021-09-17 English
News release - English.pdf
Investor Presentation Classification · 70% confidence The document is a press release announcing that PsyBio Therapeutics will present at the H.C. Wainwright 23rd Annual Global Investment Conference. It includes details about the presentation date, access to the recording, and contact information for scheduling meetings. There is no financial data, no detailed report, no voting results, no regulatory filings, or other formal report content. The document is an announcement of an investor presentation event rather than the presentation itself or a financial report. Therefore, the most appropriate classification is Investor Presentation (IP). However, since the document only announces the presentation and does not contain the presentation content itself, it is best classified as an Investor Presentation announcement. Given the options, the closest match is Investor Presentation (IP) with moderate confidence because it is about the presentation event.
2021-09-09 English
Preliminary short form prospectus – English.pdf
Capital/Financing Update Classification · 100% confidence The document is a preliminary short form base shelf prospectus for PsyBio Therapeutics Corp., dated September 1, 2021. It discusses the offering of various securities including subordinate voting shares, multiple voting shares, warrants, options, subscription receipts, debt securities, and units. The text includes detailed information about the securities, the offering process, regulatory compliance, and risk factors. This type of document is a formal offering prospectus used to raise capital and is related to financing activities. It is not an annual report, earnings release, or any other type of report but specifically a capital/financing update document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the actual prospectus, not just an announcement or a brief notice.
2021-09-01 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.